In a patient with short‑term situational anxiety and no contraindications to β‑blockers (e.g., asthma, bradycardia, heart block, severe hypotension, heart failure), should propranolol be preferred over benzodiazepines, and what are the appropriate dosing regimens for each?

Propranolol vs Benzodiazepines for Short-Term Anxiety

For short-term situational anxiety in patients without contraindications to β-blockers, benzodiazepines remain the preferred first-line pharmacological treatment, with propranolol reserved for specific scenarios involving predominantly somatic symptoms (tremor, palpitations, sweating) or performance anxiety.

Evidence-Based Recommendation

The available guideline evidence consistently supports benzodiazepines for acute anxiety management. The NICE guidelines 1 specifically recommend benzodiazepines for managing anxiety, with lorazepam 0.5-1 mg orally four times daily as needed (maximum 4 mg/24 hours) as the standard approach. This represents the most recent guideline-level evidence for acute anxiety treatment.

When to Choose Each Agent

Benzodiazepines are preferred when:

• General anxiety symptoms require sedation
• Rapid anxiolysis is needed (onset within 30-60 minutes)
• Treatment duration will be limited to 2-3 weeks maximum 2
• Patient has mixed psychological and somatic symptoms

Dosing regimen:

• Lorazepam: 0.5-1 mg orally every 6 hours as needed (reduce to 0.25-0.5 mg in elderly; maximum 2 mg/24 hours) 1
• Treatment should not exceed 2-3 weeks to minimize dependence risk 2

Propranolol is preferred when:

• Somatic symptoms predominate (tremor, palpitations, sweating) 3
• Performance anxiety or social phobia with limited, predictable triggers 4
• Patient has history of substance dependence (benzodiazepines contraindicated)
• Anxiety is characterized by increased adrenergic tone 4

Dosing regimen:

• Propranolol: 20-40 mg orally, 1-3 times daily 4
• For performance anxiety: 20-40 mg as single dose 1-2 hours before event 4, 5
• Initial dose: Start with 20 mg to minimize side effects (bradycardia, hypotension) 5

Critical Evidence Gaps and Limitations

The most recent systematic review 6 (2025) found no evidence for beneficial effect of beta-blockers compared with either placebo or benzodiazepines in patients with social phobia or panic disorder (p ≥ 0.54 for all comparisons). This high-quality meta-analysis of 179 patients contradicts older observational data and highlights that propranolol's widespread use for anxiety lacks robust evidence.

However, older research 7, 4 suggests propranolol may be useful specifically for:

1. Anxiety of moderate intensity in general practice settings
2. Recent-onset anxiety with prominent somatic symptoms
3. Short-term treatment (efficacy beyond 4 weeks unproven) 4

Safety Considerations

Benzodiazepine risks:

• Psychomotor impairment
• Dependence with prolonged use (>2-3 weeks)
• Withdrawal syndrome (rebound anxiety, seizures if abruptly stopped)
• Respiratory depression, especially with concurrent opioids 8, 9

Propranolol risks:

• Bradycardia (25% at 40 mg dose) 5
• Hypotension (10% at 40 mg dose) 5
• Masking of hypoglycemia in diabetics
• Potential depression (though recent evidence suggests protopathic bias rather than causation) 10
• Drug interactions via CYP2D6 metabolism 11

Absolute contraindications to propranolol:

• Sinus bradycardia
• Heart block >1st degree
• Cardiogenic shock
• Decompensated heart failure
• Severe hypotension
• Bronchial asthma 12

Clinical Algorithm

1. Assess anxiety type and severity:

   • Situational/acute → Consider short-term benzodiazepine
   • Performance-related with somatic symptoms → Consider propranolol
   • Chronic/generalized → Neither agent appropriate (consider SSRIs + CBT) 13

2. Screen for contraindications:

   • Check heart rate, blood pressure, cardiac history
   • Assess for respiratory disease (asthma, COPD)
   • Review substance use history

3. Initiate treatment:

   • Benzodiazepine route: Lorazepam 0.5 mg as needed, maximum 4 doses/day
   • Propranolol route: 20 mg once daily or before triggering event

4. Monitor and limit duration:

   • Benzodiazepines: Taper after 2-3 weeks maximum
   • Propranolol: Reassess efficacy after 4 weeks 4

Common Pitfalls

• Avoid prescribing benzodiazepines beyond 2-3 weeks due to dependence risk
• Avoid propranolol in patients with undiagnosed cardiac conditions without baseline ECG in elderly patients 3
• Avoid assuming propranolol is "safer" than benzodiazepines—the 2025 meta-analysis shows lack of efficacy 6
• Avoid abrupt discontinuation of either agent (taper benzodiazepines over 10-14 days; propranolol over several weeks) 8, 14